ATE466084T1 - Hla-a24-restringiertes krebsantigenpeptid - Google Patents

Hla-a24-restringiertes krebsantigenpeptid

Info

Publication number
ATE466084T1
ATE466084T1 AT03736167T AT03736167T ATE466084T1 AT E466084 T1 ATE466084 T1 AT E466084T1 AT 03736167 T AT03736167 T AT 03736167T AT 03736167 T AT03736167 T AT 03736167T AT E466084 T1 ATE466084 T1 AT E466084T1
Authority
AT
Austria
Prior art keywords
hla
cancer antigen
antigen peptide
restricted cancer
restricted
Prior art date
Application number
AT03736167T
Other languages
English (en)
Inventor
Haruo Sugiyama
Masashi Gotoh
Hideo Takasu
Original Assignee
Int Inst Cancer Immunology Inc
Chugai Pharmaceutical Co Ltd
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc, Chugai Pharmaceutical Co Ltd, Dainippon Sumitomo Pharma Co filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE466084T1 publication Critical patent/ATE466084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03736167T 2002-06-12 2003-06-12 Hla-a24-restringiertes krebsantigenpeptid ATE466084T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002171518 2002-06-12
JP2002275572 2002-09-20
PCT/JP2003/007463 WO2003106682A1 (ja) 2002-06-12 2003-06-12 Ｈｌａ−ａ２４拘束性癌抗原ペプチド

Publications (1)

Publication Number Publication Date
ATE466084T1 true ATE466084T1 (de) 2010-05-15

Family

ID=29738372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736167T ATE466084T1 (de) 2002-06-12 2003-06-12 Hla-a24-restringiertes krebsantigenpeptid

Country Status (10)

Country Link
US (2) US7420034B2 (de)
EP (1) EP1536009B1 (de)
JP (1) JP4365784B2 (de)
KR (1) KR101050703B1 (de)
CN (2) CN100408683C (de)
AT (1) ATE466084T1 (de)
AU (1) AU2003242305A1 (de)
CA (1) CA2489227C (de)
DE (1) DE60332355D1 (de)
WO (1) WO2003106682A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
EP1371664B1 (de) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
KR101399678B1 (ko) 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
CN100427502C (zh) * 2005-06-09 2008-10-22 南京大学 抗肿瘤寡肽及其制备方法和应用
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
CN102250211A (zh) 2006-02-22 2011-11-23 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2886621A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
EP2132324B1 (de) * 2007-03-02 2012-04-25 Biosante Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
US10093977B2 (en) * 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP5478260B2 (ja) 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
EP2684957A2 (de) 2009-01-08 2014-01-15 International Institute of Cancer Immunology, Inc. Doppelsträngige siRNA gegen das Krebsantigen eEF2
WO2011021503A1 (ja) * 2009-08-17 2011-02-24 国立大学法人東京大学 一過性生着ｃｔｌを含む医薬品組成物
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US10208086B2 (en) * 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
CA2884366A1 (en) 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
EA201591168A1 (ru) * 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
CN110078813B (zh) * 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2762152A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
IN2014CH00391A (de) 2013-02-05 2015-04-03 Nitto Denko Corp
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
EP2982681B8 (de) 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen-peptid-konjugat-vakzin
CN107148469B (zh) * 2014-09-24 2021-06-25 北海道公立大学法人札幌医科大学 肿瘤抗原肽
JP6723164B2 (ja) 2014-12-25 2020-07-15 株式会社癌免疫研究所 Ｔ細胞集団の改変方法
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
DK3539974T5 (en) 2016-11-09 2024-05-27 Univ Osaka Method for modifying t cell population
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
WO2020071551A1 (ja) 2018-10-05 2020-04-09 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
MX2022014249A (es) 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
EP4149953A4 (de) * 2020-05-12 2024-06-26 Lg Chem, Ltd. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2268705T3 (es) * 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
US20030092656A1 (en) * 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
EP1371664B1 (de) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド

Also Published As

Publication number Publication date
KR20050010913A (ko) 2005-01-28
US20070082860A1 (en) 2007-04-12
AU2003242305A8 (en) 2003-12-31
US7420034B2 (en) 2008-09-02
CA2489227C (en) 2012-03-13
CN101113163A (zh) 2008-01-30
KR101050703B1 (ko) 2011-07-20
AU2003242305A1 (en) 2003-12-31
EP1536009A4 (de) 2006-06-07
DE60332355D1 (de) 2010-06-10
WO2003106682A1 (ja) 2003-12-24
JPWO2003106682A1 (ja) 2005-10-13
JP4365784B2 (ja) 2009-11-18
CN100408683C (zh) 2008-08-06
HK1083866A1 (en) 2006-07-14
CA2489227A1 (en) 2003-12-24
US7666985B2 (en) 2010-02-23
CN101113163B (zh) 2010-10-06
US20090099090A1 (en) 2009-04-16
EP1536009B1 (de) 2010-04-28
EP1536009A1 (de) 2005-06-01
CN1675362A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
AU2003242305A8 (en) Hla-a24-restricted cancer antigen peptide
SI1731605T1 (sl) Peptidi antigena karcinoma izvedeni iz WT1
EP2228072A4 (de) Krebsimpfstoff-zusammensetzung
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
CY1119285T1 (el) Φορεις εμβολιου αδενοϊου χιμπατζη
DE60206512D1 (de) Rapanycin29-enole
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
NO20053999D0 (no) Survivin-avledede peptider og bruken av dem
DK1871391T3 (da) Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2019147979A3 (en) Peptides for angiogenic therapy
NO20053903D0 (no) Nukleotidlipidesterderivater.
UY26170A1 (es) Antigeno (c42) asociados a tumores
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties